LEAD

Evaluating the long-term cost-effectiveness of liraglutide vs exenatide BID in patients w/ type 2 diabetes who fail to improve w/ oral antidiabetic agents

Top

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011 Oct 19. [Epub ahead of print] The global clinical and economic burden of type 2 diabetes is substantial. Recently, clinical trials with glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide and exenatide) have shown a multifactorial clinical profile with the potential to address many of the clinical needs of patients and reduce the burden of disease.

Patient-reported outcomes in Type 2 diabetes treated with liraglutide vs exenatide, when added to metformin, sulphonylurea or both

Top

Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Diabet Med. 2011 Mar 9. doi: 10.1111/j.1464-5491.2011.03276.x. [Epub ahead of print]The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.

Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm

Top

Unger J. Clinical efficacy of GLP 1 agonists and their place in the diabetes treatment algorithm. J Am Osteopath Assoc. 2011;111(2 Suppl 1):eS2-9. Incretin-based therapies (subcutaneously administered glucagon-like peptide-1 [GLP-1] agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action with which to target the adverse effects of type 2 diabetes mellitus.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD-2 study

Top

Nauck M, Frid A, Hermansen K, et al; for the LEAD-2 Metformin Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90. The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy.

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

Top

Pratley RE, Gilbert M. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud. 2008;5(2):73-94. Until recently, the pathogenesis of type 2 diabetes mellitus (T2DM) has been conceptualized in terms of the predominant defects in insulin secretion and insulin action. It is now recognized that abnormalities in other hormones also contribute to the development of hyperglycemia.